JNJ - Neurosurgery Focused Integra LifeSciences Bolsters Its ENT Portfolio With $275M Acquisition Deal | Benzinga
Integra LifeSciences Holdings Corporation (NASDAQ: IART) agreed to acquire Acclarent Inc. from Ethicon Inc, a Johnson & Johnson (NYSE: JNJ) MedTech company, for $275 million in cash, and an additional $5 million upon the achievement of certain regulatory milestones.
Acclarent offers medical devices for ENT procedures.
The acquisition will become part of Integra's Codman Specialty Surgical (CSS) division.
The ear, nose, and throat (ENT) category is a key area of strategic interest and highly complementary to the neurosurgery segment.
"This acquisition presents Integra ...